Foley & Lardner LLP today released Antibody Drug Conjugates Keep Growing: What You Need to Know, a guide that answers many business and legal questions about the rapid expansion of this area of technology.
Licensing deals for antibody drug conjugates (ADCs), a class of chemotherapy medicines used in the treatment of cancers, are on the rise and worldwide ADCs sales are projected to reach US$20-30 billion per year in the near future. These drugs combine an antibody and cancer treating drug to minimize the impact of chemotherapy on healthy tissue, while maximizing their impact on the cancer, to reduce the overall negative impact on a patient.
Although ADCs have been used for more than two decades, continued development of the technology has given regulators, pharmaceutical companies, and doctors more confidence in the clinical efficacy of these treatments, but has also raised more questions. Companies now need to know how to navigate a myriad of concerns related to ADCs/antibody therapeutics, including deals and licensing requirements, patent/IP challenges, and issues related to clinical trials, FDA/regulations, and litigation.
With more investments from the pharmaceutical industry and more than 140 new ADCs currently in clinical development, companies touching this space should keep current on the progresses being made and how their businesses may be affected. This guide unpacks the most pertinent questions and issues, with articles including:
- Antibody Drug Conjugates: An FDA Perspective
- Strategies For Patenting Antibody-Drug Conjugate Inventions
- Deals and Licensing for Antibody-Drug Conjugates
- Antibody-Drug Conjugate Litigation
- Clinical Trial Issues for Antibody Drug Conjugates/Antibody Therapeutics
Access the full guide here.
Foley’s Health Care & Life Sciences Sector is comprised of more than 200 attorneys with decades of collective in-house experience at health care providers and vendors, pharmaceutical and biotechnology firms, and key state and federal government agencies. Foley is primed to strategically advise health care and life sciences companies through every step of their journey and all stages of their lifecycle. The firm’s Pharmaceuticals and Other Regulated Drugs team is at the forefront of trends in this field and works with clients on intellectual property, litigation, transactional, clinical trials, and FDA regulatory work.
Foley’s Innovative Technology Sector consists of a cross-disciplinary group of over 200 attorneys who understand the impact of business and market trends and can help navigate the nuances of continued technological advancements. The firm’s Health Tech & Genomics team assists clients with questions surrounding today’s groundbreaking developments, leveraging lawyers’ dual backgrounds in science and law to solve problems and deliver solutions.
关于富理达律师事务所
Foley & Lardner LLP 是一家杰出的律师事务所，处于能源、医疗保健和生命科学、创新技术和制造业的中心。我们将目光投向法律之外，关注客户面临的不断变化的需求，并作为值得信赖的业务顾问，为客户提供创新、实用和有效的解决方案。我们在全球 26 个办事处拥有 1,100 名律师，可为客户提供从公司法律顾问到知识产权工作和诉讼支持的全方位服务，为客户的所有需求提供一站式解决方案。近两个世纪以来，富理达一直致力于提供最高水平的创新法律服务，以及对我们的员工、公司、客户和我们所服务的社区的管理。